The grants, finalized on October 15, 2026, function as a material condition for the two individuals joining the corporation. Under the terms of the agreement, the shares are structured to vest in equal annual installments over the next three years, provided the recipients maintain continuous employment with the firm throughout that period.

This specific equity allocation follows the governance requirements of the 2026 Inducement Plan, which restricts such awards to individuals who were not previously employed by the company. QuidelOrtho, which maintains a portfolio spanning clinical chemistry and molecular testing, utilizes these inducement grants to integrate new professional expertise into its operations.